

Princeton – Recall of Irbesartan-Containing Products

- On January 18, 2019, [Princeton announced](#) a voluntary, patient-level recall of several lots of [irbesartan](#) and [irbesartan/hydrochlorothiazide](#) (HCTZ) tablets due to the detection of trace amounts of an unexpected impurity, identified as N-nitrosodiethylamine (NDEA), found in an active pharmaceutical ingredient (API) manufactured by Zhejiang Huahai Pharmaceuticals.
- NDEA is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probable human carcinogen as per International Agency for Research on Cancer classification.

— Refer to the [FDA site](#) for updates regarding angiotensin II receptor blocker recalls.

- The recalled products are listed below:

Product Description	NDC#	Lot# (Expiration Date)
Irbesartan 300 mg tablets, 90 count bottle	43547-376-09	331B18009 (2/2021)
Irbesartan/HCTZ 300 mg/12.5 mg tablets, 30 count bottle	43547-331-03	327A18001 (3/2021); 327A18002 (3/2021)
Irbesartan/HCTZ 300 mg/12.5 mg tablets, 90 count bottle	43547-331-09	327B18008 (3/2021); 327B18009 (3/2021)
Irbesartan/HCTZ 150 mg/12.5 mg tablets, 30 count bottle	43547-330-03	325D18004 (3/2021); 325D18005 (3/2021)
Irbesartan/HCTZ 150 mg/12.5 mg tablets, 90 count bottle	43547-330-09	325B18004 (3/2021)

- Irbesartan and irbesartan/HCTZ are used to treat hypertension (HTN). Irbesartan is also used for the treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria (> 300 mg/day) in patients with type 2 diabetes and HTN.
- Patients should contact their pharmacist or physician who can advise them about an alternative treatment prior to returning their medication. Patients who are on irbesartan or irbesartan/HCTZ should continue taking their medication, as the risk of harm to a patient’s health may be higher if the treatment is stopped immediately without any alternative treatment.
- Patients should contact their healthcare provider if they have experienced any problems that may be related to using the recalled irbesartan or irbesartan/HCTZ.
- Anyone with an existing inventory of the recalled product should stop use and distribution, and quarantine the product immediately.

- For more information regarding this recall, contact Solco at **1-888-871-7116**.
 - Solco is a fully owned subsidiary of Princeton and Zhejiang Huahai Pharmaceutical.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.